Solenne MAQUERE
Naturopath specialized in women's health
Wellness Director at PEMLAB
Appointments : here
----------------------------
"I usually recommend PEA to my consultants suffering from endometriosis or chronic pain, because it offers a natural, well-tolerated solution that is not habit-forming. It reduces both pain and inflammation, two key aspects of naturopathic endometriosis care. PEA effectively reduces inflammation and acts directly on nerve cells to reduce pain, enabling women with endometriosis to feel better quickly. What's more, its action on the endocannabinoid system reinforces the body's natural mechanisms for managing these symptoms, in a way making the body autonomous in the face of disease. To enhance its effects, it can be combined with other supplements such as omega-3, turmeric, magnesium, vitamin D or melatonin for pain-related sleep disorders."
------------------------------------------
Independent clinical research supports OptiPEA® as a natural pain ingredient
Medical University of Graz, Austria
------------------------------------------
The study entitled "The Effect of Palmitoylethanolamide on Pain Intensity, Central and Peripheral Sensitization, and Pain Modulation in Healthy Volunteers-A Randomized Double-Blinded Placebo-Controlled Crossover Trial" examines the impact of palmitoylethanolamide (PEA), a natural substance, on pain management. Used as a "dietary food for special medical purposes", PEA is known for its analgesic, anti-inflammatory and neuroprotective effects, making its study in the context of pain management particularly relevant.
Thestudy included 14 healthy volunteers in a double-blind, placebo-controlled crossover trial, where participants received either PEA (3×400 mg daily) or placebo for 4 weeks. The aim was to determine the action of PEA on different aspects of pain, using an established pain model, "repeated phasic heat application", adapted to assess analgesic and antihyperalgesic effects in healthy volunteers. Parameters assessed included peripheral and central sensitization, as well as pain modulation.
Results showed a significant reduction in pain with repetitive heat, increased tolerance to cold pain, increased tolerance to pressure pain and improved modulation of conditioned pain after AEP treatment. In addition, PEA decreased the wind-up ratio and mean allodynia distance, indicating an action on central and peripheral sensitization as well as pain modulation.
This study demonstrated that PEA possesses clinically relevant analgesic properties, acting on peripheral and central mechanisms as well as pain modulation. No side effects or adverse events were reported by participants, underlining PEA's high tolerability profile. These findings support the potential use of PEA in the treatment of various chronic pain conditions, due to its ability to reduce pain sensitization and improve pain modulation.
The full study is available at https://www.mdpi.com/2072-6643/14/19/4084
